Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2010 Jul;7(3):264–274. doi: 10.1016/j.nurt.2010.05.005

Fragile X: Leading the way for targeted treatments in autism

Lulu W Wang 1,2,✉, Elizabeth Berry-Kravis 3,4,5, Randi J Hagerman 1,2
PMCID: PMC4084556  NIHMSID: NIHMS209684  PMID: 20643379

Summary

Two different mutations in the FMR1 gene may lead to autism. The full mutation, with >200 CGG repeats in the 5′ end of FMR1, leads to hypermethylation and transcriptional silencing of FMR1, resulting in absence or deficiency of the protein product, FMRP. Deficiency of FMRP in the brain causes fragile X syndrome (FXS). Autism occurs in approximately 30% of those with FXS, and pervasive developmental disorders-not otherwise specified occur in an additional 30%. FMRP is an RNA binding protein that modulates receptor-mediated dendritic translation; deficiency leads to dysregulation of many proteins important for synaptic plasticity. Group I metabotropic glutamate receptor (mGluR1/5) activated translation is upregulated in FXS, and new targeted treatments that act on this system include mGluR5 antagonists and GABA agonists, which may reverse the cognitive and behavioral deficits in FXS. Matrix metalloproteinase 9 (MMP-9) is one of the proteins elevated in FXS, and minocycline reduces excess MMP-9 activity in the Fmr1 knockout mouse model of FXS. Both minocycline and mGluR5 antagonists are currently being evaluated in patients with FXS through controlled treatment trials. The premutation (55–200 CGG repeats) may also contribute to the mechanism of autism in approximately 10% of males and 2–3% of females. Premutations with <150 repeats exert cellular effects through a different molecular mechanism, one that involves elevated levels of FMR1 mRNA, CGG-mediated toxicity to neurons, early cell death, and fragile X-associated tremor/ataxia syndrome. In those with large premutations (150–200), lowered levels of FMRP also occur.

Key Words: Fragile X syndrome, autism, ASD, mGluR, GABA, treatment, animal model

References

  • 1.Hagerman RJ, Rivera SM, Hagerman PJ. The fragile X family of disorders: a model for autism and targeted treatments. Curr Pediatr Rev. 2008;4:40–52. doi: 10.2174/157339608783565770. [DOI] [Google Scholar]
  • 2.Reddy KS. Cytogenetic abnormalities and fragile-X syndrome in autism spectrum disorder. BMC Med Genet. 2005;6:3–3. doi: 10.1186/1471-2350-6-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.van Karnebeek CD. Jansweijer MC, Leenders AG, Offringa M, Hennekam RC. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet. 2005;13:6–25. doi: 10.1038/sj.ejhg.5201279. [DOI] [PubMed] [Google Scholar]
  • 4.Femandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11:324–329. doi: 10.2353/jmoldx.2009.080173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hagerman PJ. The fragile X prevalence paradox [Erratum in: J Med Genet 2008;45:768] J Med Genet. 2008;45:498–499. doi: 10.1136/jmg.2008.059055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dombrowski C, Lévesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11:371–378. doi: 10.1093/hmg/11.4.371. [DOI] [PubMed] [Google Scholar]
  • 7.Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65:905–914. doi: 10.1016/0092-8674(91)90397-H. [DOI] [PubMed] [Google Scholar]
  • 8.Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci. 2005;25:5087–5095. doi: 10.1523/JNEUROSCI.0093-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60:201–214. doi: 10.1016/j.neuron.2008.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tassone F, Hagerman RJ, Iklé DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet. 1999;84:250–261. doi: 10.1002/(SICI)1096-8628(19990528)84:3&#x0003c;250::AID-AJMG17&#x0003e;3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  • 11.Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004;10:31–41. doi: 10.1002/mrdd.20006. [DOI] [PubMed] [Google Scholar]
  • 12.Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr. 2001;22:409–417. doi: 10.1097/00004703-200112000-00008. [DOI] [PubMed] [Google Scholar]
  • 13.Kaufmann WE, Cortell R, Kau AS, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet. 2004;129A:225–234. doi: 10.1002/ajmg.a.30229. [DOI] [PubMed] [Google Scholar]
  • 14.Loesch DZ, Bui QM, Dissanayake C, et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev. 2007;31:315–326. doi: 10.1016/j.neubiorev.2006.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Garcia-Nonell C, Ratera ER, Harris S, et al. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. Am J Med Genet A. 2008;146A:1911–1916. doi: 10.1002/ajmg.a.32290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet. 1996;58:1025–1032. [PMC free article] [PubMed] [Google Scholar]
  • 17.Bennetto L, Pennington BF. Neuropsychology. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University Press; 2002. pp. 206–248. [Google Scholar]
  • 18.Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University Press; 2002. pp. 3–109. [Google Scholar]
  • 19.Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ. Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet. 1991;38:269–274. doi: 10.1002/ajmg.1320380221. [DOI] [PubMed] [Google Scholar]
  • 20.Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005;20:402–412. doi: 10.1093/humrep/deh635. [DOI] [PubMed] [Google Scholar]
  • 21.Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril. 2007;87:456–465. doi: 10.1016/j.fertnstert.2006.09.004. [DOI] [PubMed] [Google Scholar]
  • 22.Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000;66:6–15. doi: 10.1086/302720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hagerman RJ. Fragile X Syndrome. In: Cassidy SB, Allanson JE, editors. Management of genetic syndromes. 3rd ed. New York: Wiley & Sons; 2010. pp. 397–411. [Google Scholar]
  • 24.Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004;291:460–469. doi: 10.1001/jama.291.4.460. [DOI] [PubMed] [Google Scholar]
  • 25.Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004;74:1051–1056. doi: 10.1086/420700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A:1009–1016. doi: 10.1002/ajmg.a.32060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rodriguez-Revenga L, Madrigal I, Alegret M, Santos M, Milà M. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet. 2008;18:153–155. doi: 10.1097/YPG.0b013e3282f97e0b. [DOI] [PubMed] [Google Scholar]
  • 28.Arocena DG, Iwahashi CK, Won N, et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet. 2005;14:3661–3671. doi: 10.1093/hmg/ddi394. [DOI] [PubMed] [Google Scholar]
  • 29.Garcia-Arocena D, Yang JE, Brouwer JR, et al. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet. 2010;19:299–312. doi: 10.1093/hmg/ddp497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS) Neurology. 2007;69:851–859. doi: 10.1212/01.wnl.0000269781.10417.7b. [DOI] [PubMed] [Google Scholar]
  • 31.Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS) Brain. 2006;129:243–255. doi: 10.1093/brain/awh683. [DOI] [PubMed] [Google Scholar]
  • 32.Greco CM, Soontrapomchai K, Wirojanan J, Gould JE, Hagerman PJ, Hagerman RJ. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol. 2007;177:1434–1437. doi: 10.1016/j.juro.2006.11.097. [DOI] [PubMed] [Google Scholar]
  • 33.Gokden M, Al-Hinti JT, Harik SI. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS) Neuropathology. 2009;29:280–284. doi: 10.1111/j.1440-1789.2008.00948.x. [DOI] [PubMed] [Google Scholar]
  • 34.Chen Y, Tassone F, Berman RF, et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet. 2010;19:196–208. doi: 10.1093/hmg/ddp479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006;27(2 Suppl):S137–S144. doi: 10.1097/00004703-200604002-00012. [DOI] [PubMed] [Google Scholar]
  • 36.Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet. 2003;121B:119–127. doi: 10.1002/ajmg.b.20030. [DOI] [PubMed] [Google Scholar]
  • 37.Bailey DB, Raspa M. Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008;146A:2060–2069. doi: 10.1002/ajmg.a.32439. [DOI] [PubMed] [Google Scholar]
  • 38.Hunter JE, Allen EG, Abramowitz A, et al. No evidence for a difference in neuropsychological profile among carriers and non-carriers of the FMR1 premutation in adults under the age of 50. Am J Hum Genet. 2008;83:692–702. doi: 10.1016/j.ajhg.2008.10.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Grigsby J, Brega AG, Engle K, et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology. 2008;22:48–60. doi: 10.1037/0894-4105.22.1.48. [DOI] [PubMed] [Google Scholar]
  • 40.Cornish KM, Kogan CS, Li L, Turk J, Jacquemont S, Hagerman RJ. Lifespan changes in working memory in fragile X premutation males. Brain Cogn. 2009;69:551–558. doi: 10.1016/j.bandc.2008.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Moore CJ, Daly EM, Schmitz N, et al. A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia. 2004;42:1934–1947. doi: 10.1016/j.neuropsychologia.2004.05.002. [DOI] [PubMed] [Google Scholar]
  • 42.Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord. 2007;37:738–747. doi: 10.1007/s10803-006-0205-z. [DOI] [PubMed] [Google Scholar]
  • 43.Bourgeois J, Seritan A, Casillas E, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry (in press). [DOI] [PMC free article] [PubMed]
  • 44.Roberts JE, Bailey DB, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:130–139. doi: 10.1002/ajmg.b.30786. [DOI] [PubMed] [Google Scholar]
  • 45.Bourgeois JA, Coffey SM, Rivera SM, et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry. 2009;70:852–862. doi: 10.4088/JCP.08r04476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Brouwer JR, Severijnen E, de Jong FH, et al. Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology. 2008;33:863–873. doi: 10.1016/j.psyneuen.2008.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Adams PE, Adams JS, Nguyen DV, et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(3):775–785. doi: 10.1002/ajmg.b.31046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Miller LJ, McIntosh DN, McGrath J, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet. 1999;83:268–279. doi: 10.1002/(SICI)1096-8628(19990402)83:4&#x0003c;268::AID-AJMG7&#x0003e;3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 49.Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659–685. doi: 10.1007/BF02172145. [DOI] [PubMed] [Google Scholar]
  • 50.Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles, CA: Western Psychological Services; 1999. [Google Scholar]
  • 51.Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008;113:427–438. doi: 10.1352/2008.113:427-438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Hagerman RJ, Jackson AW, Levitas A, Rimland B, Braden M. An analysis of autism in fifty males with the fragile X syndrome. Am J Med Genet A. 1986;23:359–374. doi: 10.1002/ajmg.1320230128. [DOI] [PubMed] [Google Scholar]
  • 53.Bailey DB, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L. Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord. 1998;28:499–508. doi: 10.1023/A:1026048027397. [DOI] [PubMed] [Google Scholar]
  • 54.Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics. 1995;95:744–752. [PubMed] [Google Scholar]
  • 55.Kerby DS, Dawson BL. Autistic features, personality, and adaptive behavior in males with the fragile X syndrome and no autism. Am J Ment Retard. 1994;98:455–462. [PubMed] [Google Scholar]
  • 56.Merenstein SA, Sobesky WE, Taylor AK, Riddle JE, Tran HX, Hagerman RJ. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet. 1996;64:388–394. doi: 10.1002/(SICI)1096-8628(19960809)64:2&#x0003c;388::AID-AJMG31&#x0003e;3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 57.Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am J Ment Retard. 2008;113:44–53. doi: 10.1352/0895-8017(2008)113[44:CSAABI]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 58.Bailey A, Bolton P, Butler L, et al. Prevalence of the fragile X anomaly amongst autistic twins and singletons. J Child Psychol Psychiatry. 1993;34:673–688. doi: 10.1111/j.1469-7610.1993.tb01064.x. [DOI] [PubMed] [Google Scholar]
  • 59.Bailey A, Phillips W, Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J Child Psychol Psychiatry. 1996;37:89–126. doi: 10.1111/j.1469-7610.1996.tb01381.x. [DOI] [PubMed] [Google Scholar]
  • 60.Dykens EM, Volkmar FR. Medical conditions associated with autism. In: Cohen DJ, Volkmar FR, editors. Handbook of autism and pervasive developmental disorders. 2nd ed. New York: John Wiley & Sons; 1997. pp. 388–410. [Google Scholar]
  • 61.Nowicki ST, Tassone F, Ono MY, et al. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr. 2007;28:133–138. doi: 10.1097/01.DBP.0000267563.18952.c9. [DOI] [PubMed] [Google Scholar]
  • 62.Roberts J, Price J, Barnes E, et al. Receptive vocabulary, expressive vocabulary, and speech production of boys with fragile X syndrome in comparison to boys with Down syndrome. Am J Ment Retard. 2007;112:177–193. doi: 10.1352/0895-8017(2007)112[177:RVEVAS]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 63.Kau AS, Tierney E, Bukelis I, et al. Social behavior profile in young males with fragile X syndrome: characteristics and specificity. Am J Med Genet. 2004;126A:9–17. doi: 10.1002/ajmg.a.20218. [DOI] [PubMed] [Google Scholar]
  • 64.Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006;140A:1804–1813. doi: 10.1002/ajmg.a.31286. [DOI] [PubMed] [Google Scholar]
  • 65.Lewis P, Abbeduto L, Murphy M, et al. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res. 2006;50:532–545. doi: 10.1111/j.1365-2788.2006.00803.x. [DOI] [PubMed] [Google Scholar]
  • 66.Chiu S, Wegelin JA, Blank J, et al. Early acceleration of head circumference in children with fragile X syndrome and autism. J Dev Behav Pediatr. 2007;28:31–35. doi: 10.1097/01.DBP.0000257518.60083.2d. [DOI] [PubMed] [Google Scholar]
  • 67.Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA. 2003;290:337–344. doi: 10.1001/jama.290.3.337. [DOI] [PubMed] [Google Scholar]
  • 68.Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005;42:318–321. doi: 10.1136/jmg.2004.024646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Reiss AL, Freund L, Tseng JE, Joshi PK. Neuroanatomy in fragile X females: the posterior fossa. Am J Hum Genet. 1991;49:279–288. [PMC free article] [PubMed] [Google Scholar]
  • 70.Mostofsky SH, Mazzocco MM, Aakalu G, Warsofsky IS, Denckla MB, Reiss AL. Decreased cerebellar posterior vermis size in fragile X syndrome: correlation with neurocognitive performance. Neurology. 1998;50:121–130. doi: 10.1212/wnl.50.1.121. [DOI] [PubMed] [Google Scholar]
  • 71.Murakami JW, Courchesne E, Press GA, Yeung-Courchesne R, Hesselink JR. Reduced cerebellar hemisphere size and its relationship to vermal hypoplasia in autism. Arch Neurol. 1989;46:689–694. doi: 10.1001/archneur.1989.00520420111032. [DOI] [PubMed] [Google Scholar]
  • 72.Ciesielski KT, Harris RJ, Hart BL, Pabst HF. Cerebellar hypoplasia and frontal lobe cognitive deficits in disorders of early childhood. Neuropsychologia. 1997;35:643–655. doi: 10.1016/S0028-3932(96)00119-4. [DOI] [PubMed] [Google Scholar]
  • 73.Pierce K, Courchesne E. Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism. Biol Psychiatry. 2001;49:655–664. doi: 10.1016/S0006-3223(00)01008-8. [DOI] [PubMed] [Google Scholar]
  • 74.Mazzocco MM, Kates WR, Baumgardner TL, Freund LS, Reiss AL. Autistic behaviors among girls with fragile X syndrome. J Autism Dev Disord. 1997;27:415–435. doi: 10.1023/A:1025857422026. [DOI] [PubMed] [Google Scholar]
  • 75.Van Essen DC, Maunsell HH. Hierarchical organization of the functional streams in the visual cortex. Trends Neurosci. 1983;6:370–375. doi: 10.1016/0166-2236(83)90167-4. [DOI] [Google Scholar]
  • 76.Sagi D, Julesz B. “Where” and “what” in vision. Science. 1985;228:1217–1219. doi: 10.1126/science.4001937. [DOI] [PubMed] [Google Scholar]
  • 77.Kogan CS, Boutet I, Cornish KM, et al. Differential impact of the FMR1 gene on visual processing in fragile X syndrome. Brain. 2004;127:591–601. doi: 10.1093/brain/awh069. [DOI] [PubMed] [Google Scholar]
  • 78.Spencer J, O’Brien J, Riggs K, Braddick O, Atkinson J, Wattam-Bell J. Motion processing in autism: evidence for a dorsal stream deficiency. Neuroreport. 2000;11:2765–2767. doi: 10.1097/00001756-200008210-00031. [DOI] [PubMed] [Google Scholar]
  • 79.Bertone A, Mottron L, Jelenic P, Faubert J. Motion perception in autism: a “complex” issue. J Cogn Neurosci. 2003;15:218–225. doi: 10.1162/089892903321208150. [DOI] [PubMed] [Google Scholar]
  • 80.Blake R, Turner LM, Smoski MJ, Pozdol SL, Stone WL. Visual recognition of biological motion is impaired in children with autism. Psychol Sci. 2003;14:151–157. doi: 10.1111/1467-9280.01434. [DOI] [PubMed] [Google Scholar]
  • 81.Hazlett HC, Poe MD, Lightbody AA, et al. Teasing apart the heterogeneity of autism: same behavior, different brains in toddlers with fragile X syndrome and autism. J Neurodev Disord. 2009;1:81–90. doi: 10.1007/s11689-009-9009-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Hagerman RJ, Miller LJ, McGrath-Clarke J, et al. Influence of stimulants on electrodermal studies in fragile X syndrome. Microsc Res Tech. 2002;57:168–173. doi: 10.1002/jemt.10067. [DOI] [PubMed] [Google Scholar]
  • 83.Roberts JE, Boccia ML, Bailey DB, Hatton DD, Skinner M. Cardiovascular indices of physiological arousal in boys with fragile X syndrome. Dev Psychobiol. 2001;39:107–123. doi: 10.1002/dev.1035. [DOI] [PubMed] [Google Scholar]
  • 84.Roberts JE, Boccia ML, Hatton DD, Skinner ML, Sideris J. Temperament and vagal tone in boys with fragile X syndrome. J Dev Behav Pediatr. 2006;27:193–201. doi: 10.1097/00004703-200606000-00003. [DOI] [PubMed] [Google Scholar]
  • 85.Boccia ML, Roberts JE. Behavior and autonomic nervous system function assessed via heart period measures: the case of hyperarousal in boys with fragile X syndrome. Behav Res Methods, Instrum Comput. 2000;32:5–10. doi: 10.3758/BF03200783. [DOI] [PubMed] [Google Scholar]
  • 86.Cohen IL. A theoretical analysis of the role of hyperarousal in the learning and behavior of fragile X males. Ment Retard Dev Disabil Res Rev. 1995;1:286–291. doi: 10.1002/mrdd.1410010410. [DOI] [Google Scholar]
  • 87.Frankland PW, Wang Y, Rosner B, et al. Sensorimotor gating abnormalities in young males with fragile X syndrome and FMR1-knockout mice. Mol Psychiatry. 2004;9:417–425. doi: 10.1038/sj.mp.4001432. [DOI] [PubMed] [Google Scholar]
  • 88.Hessl D, Berry-Kravis E, Cordeiro L, et al. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:545–53. doi: 10.1002/ajmg.b.30858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Perry W, Minassian A, Lopez B, Maron L, Lincoln A. Sensorimotor gating deficits in adults with autism. Biol Psychiatry. 2007;61:482–486. doi: 10.1016/j.biopsych.2005.09.025. [DOI] [PubMed] [Google Scholar]
  • 90.Postma P, Kumari V, Hines M, Gray JA. The relationship between prepulse detection and prepulse inhibition of the acoustic startle reflex. Psychophysiology. 2001;38:377–382. doi: 10.1111/1469-8986.3830377. [DOI] [PubMed] [Google Scholar]
  • 91.Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci U S A. 2001;98:7101–7106. doi: 10.1073/pnas.141145998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron. 2005;45:753–764. doi: 10.1016/j.neuron.2005.01.038. [DOI] [PubMed] [Google Scholar]
  • 93.Bakker CE, Oostra BA. Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res. 2003;100:111–123. doi: 10.1159/000072845. [DOI] [PubMed] [Google Scholar]
  • 94.Zhang YQ, Bailey AM, Matthies HJ, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell. 2001;107:591–603. doi: 10.1016/S0092-8674(01)00589-X. [DOI] [PubMed] [Google Scholar]
  • 95.Dockendorff TC, Su HS, McBride SM, et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron. 2002;34:973–984. doi: 10.1016/S0896-6273(02)00724-9. [DOI] [PubMed] [Google Scholar]
  • 96.Morales J, Hiesinger PR, Schroeder AJ, et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron. 2002;34:961–972. doi: 10.1016/S0896-6273(02)00731-6. [DOI] [PubMed] [Google Scholar]
  • 97.Lee A, Li W, Xu K, Bogert BA, Su K, Gao FB. Control of dendritic development by the Drosophila fragile X-related gene involves the small GTPase Rac1. Development. 2003;130:5543–5552. doi: 10.1242/dev.00792. [DOI] [PubMed] [Google Scholar]
  • 98.Dolen G, Osterweil E, Rao BS, et al. Collection of fragile X syndrome in mice. Neuron. 2007;56:955–962. doi: 10.1016/j.neuron.2007.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Bear MF, Dolen G, Osterweil E, Nagarajan N. Fragile X: translation in action. Neuropsychopharmacology. 2008;33:84–87. doi: 10.1038/sj.npp.1301610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Penagarikano O, Mulle JG, Warren ST. The pathophysiology of fragile X syndrome. Annu Rev Genomics Hum Genet. 2007;8:109–129. doi: 10.1146/annurev.genom.8.080706.092249. [DOI] [PubMed] [Google Scholar]
  • 101.Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370–377. doi: 10.1016/j.tins.2004.04.009. [DOI] [PubMed] [Google Scholar]
  • 102.Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 2005;4:393–398. doi: 10.1111/j.1601-183X.2005.00135.x. [DOI] [PubMed] [Google Scholar]
  • 103.Comery TA, Harris JB, Willems PJ, et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A. 1997;94:5401–5404. doi: 10.1073/pnas.94.10.5401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. J Neurosci. 2001;21:5139–5146. doi: 10.1523/JNEUROSCI.21-14-05139.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Irwin SA, Patel B, Idupulapati M, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet A. 2001;98:161–167. doi: 10.1002/1096-8628(20010115)98:2&#x0003c;161::AID-AJMG1025&#x0003e;3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 106.Knott GW, Holtmaat A, Wilbrecht L, Welker E, Svoboda K. Spine growth precedes synapse formation in the adult neocortex in vivo. Nat Neurosci. 2006;9:1117–1124. doi: 10.1038/nn1747. [DOI] [PubMed] [Google Scholar]
  • 107.Linden DJ. Input-specific induction of cerebellar long-term depression does not require presynaptic alteration. Learn Mem. 1994;1:121–128. [PubMed] [Google Scholar]
  • 108.Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev. 1999;29:83–120. doi: 10.1016/S0165-0173(98)00050-2. [DOI] [PubMed] [Google Scholar]
  • 109.Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99:7746–7750. doi: 10.1073/pnas.122205699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Zheng F, Gallagher JP. Metabotropic glutamate receptors are required for the induction of long-term potentiation. Neuron. 1992;9:163–172. doi: 10.1016/0896-6273(92)90231-2. [DOI] [PubMed] [Google Scholar]
  • 111.Fendt M, Schmid S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur J Neurosci. 2002;15:1535–1541. doi: 10.1046/j.1460-9568.2002.01988.x. [DOI] [PubMed] [Google Scholar]
  • 112.Koekkoek SK, Yamaguchi K, Milojkovic BA, et al. Deletion of FMR1 in Purkinje]ells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron. 2005;47:339–352. doi: 10.1016/j.neuron.2005.07.005. [DOI] [PubMed] [Google Scholar]
  • 113.Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A. 2007;104:15537–15542. doi: 10.1073/pnas.0707484104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Irwin SA, Galvez R, Weiler IJ, Beckel-Mitchener A, Greenough WT. Brain structure and functions of FMR1 protein. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University Press; 2002. pp. 191–205. [Google Scholar]
  • 115.Beckel-Mitchener A, Greenough WT. Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10:53–59. doi: 10.1002/mrdd.20009. [DOI] [PubMed] [Google Scholar]
  • 116.Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci. 2005;25:8048–8055. doi: 10.1523/JNEUROSCI.1777-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Gasparini F, Lingenhohl K, Stoehr N, et al. 2-Methyl-6-(phenyl-ethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999;38:1493–1503. doi: 10.1016/S0028-3908(99)00082-9. [DOI] [PubMed] [Google Scholar]
  • 118.Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49:1053–1066. doi: 10.1016/j.neuropharm.2005.06.004. [DOI] [PubMed] [Google Scholar]
  • 119.de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008;31:127–132. doi: 10.1016/j.nbd.2008.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Paredes RG, Agmo A. GABA and behavior: the role of receptor subtypes [Erratum in: Neurosci Biobehav Rev 1992;16:425] Neurosci Biobehav Rev. 1992;16:145–170. doi: 10.1016/S0149-7634(05)80177-0. [DOI] [PubMed] [Google Scholar]
  • 121.Mihalek RM, Banerjee PK, Korpi ER, et al. Attenuated sensitivity to neuroactive steroids in γ-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci U S A. 1999;96:12905–12910. doi: 10.1073/pnas.96.22.12905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptor. J Pharmacol Exp Ther. 1997;280:1284–1295. [PubMed] [Google Scholar]
  • 123.Miyashiro KY, Beckel-Mitchener A, Purk TP, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417–431. doi: 10.1016/S0896-6273(03)00034-5. [DOI] [PubMed] [Google Scholar]
  • 124.D’Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121:238–245. doi: 10.1016/j.brainres.2006.08.115. [DOI] [PubMed] [Google Scholar]
  • 125.Gantois I, Vandesompele J, Speleman F, et al. Expression profiling suggests underexpression of the GABAA receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis. 2006;21:346–357. doi: 10.1016/j.nbd.2005.07.017. [DOI] [PubMed] [Google Scholar]
  • 126.Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008;4:256–263. doi: 10.1038/nchembio.78. [DOI] [PubMed] [Google Scholar]
  • 127.Isaacson JS, Hille B. GABAB-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron. 1997;18:143–152. doi: 10.1016/S0896-6273(01)80053-2. [DOI] [PubMed] [Google Scholar]
  • 128.Sohn JW, Lee D, Cho H, et al. Receptor-specific inhibition of GABAB-activated K+ currents by muscarinic and metabotropic glutamate receptors in immature rat hippocampus. J Physiol. 2007;580:411–422. doi: 10.1113/jphysiol.2006.125914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Primrose DA. Treatment of self-injurious behaviour with a GABA (γ-aminobutyric acid) analogue. J Ment Defic Res. 1979;23:163–173. doi: 10.1111/j.1365-2788.1979.tb00991.x. [DOI] [PubMed] [Google Scholar]
  • 130.Paylor R. Pharmacological modification of behavioral responses in the fragile X mouse model. Proc Int Fragile X Conf 11th. 2008;11:1052–1052. [Google Scholar]
  • 131.Pacey LK, Heximer SP, Hampson DR. Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol. 2009;76:18–24. doi: 10.1124/mol.109.056127. [DOI] [PubMed] [Google Scholar]
  • 132.Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther. 2005;315:711–721. doi: 10.1124/jpet.105.089839. [DOI] [PubMed] [Google Scholar]
  • 133.Beny-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266–271. doi: 10.1136/jmg.2008.063701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Hagerman RJ, Beny-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123:378–390. doi: 10.1542/peds.2008-0317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Beny-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293–302. doi: 10.1097/DBP.0b013e31817dc447. [DOI] [PubMed] [Google Scholar]
  • 136.Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci. 2002;19:138–151. doi: 10.1006/mcne.2001.1085. [DOI] [PubMed] [Google Scholar]
  • 137.Lauterborn JC, Rex CS, Kramár E, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci. 2007;27:10685–10694. doi: 10.1523/JNEUROSCI.2624-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006;16:525–540. doi: 10.1089/cap.2006.16.525. [DOI] [PubMed] [Google Scholar]
  • 139.Bilousova TV, Rusakov DA, Ethell DW, Ethell IM. Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J Neurochem. 2006;97:44–56. doi: 10.1111/j.1471-4159.2006.03701.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46:94–102. doi: 10.1136/jmg.2008.061796. [DOI] [PubMed] [Google Scholar]
  • 141.Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil (in press). [DOI] [PMC free article] [PubMed]
  • 142.McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–321. doi: 10.1056/NEJMoa013171. [DOI] [PubMed] [Google Scholar]
  • 143.Aman MG, Gharabawi GM. Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry. 2004;65:1197–1210. doi: 10.4088/JCP.v65n0907. [DOI] [PubMed] [Google Scholar]
  • 144.Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–1540. doi: 10.1542/peds.2008-3782. [DOI] [PubMed] [Google Scholar]
  • 145.Erickson CA, Kohn AE, Diener JT, Stigler KA, Posey DJ, McDougle CJ. A prospective, 12-week open-label study of aripiprazole in fragile X syndrome. Proc Int Fragile X Conf 11th. 2008;11:1065–1100. [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES